Giulia Schiroli, PhD, integrates expertise in stem cell biology, genome engineering, and delivery to develop novel therapeutic applications with a focus on the hematopoietic system.
Dr. Schiroli trained at the San Raffaele Telethon Institute for Gene Therapy, where she contributed to key advances in precise genome editing of hematopoietic stem cells (HSCs). Her work ranged from preclinical modeling of gene-correction approaches for primary immunodeficiencies to defining molecular signatures induced by gene editing and developing strategies to enhance the fitness of edited cells. As a fellow at Massachusetts General Hospital, she applied genome engineering tools to investigate HSC clonal fitness and lineage bias, with the goal of identifying approaches to prevent malignant transformation and improve stem cell potency. She is currently an Associate Director at Tessera Therapeutics, where she leads a research program sponsored by the Gates Foundation developing an in vivo HSC gene-correction approach for the treatment of sickle cell disease by combining advanced genome engineering with targeted, non-viral delivery technologies.